Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07605884

Denys-Drash Syndrome and Risk of Post-transplant Lymphoproliferative Disorder

Denys-Drash syndrome is a rare genetic disorder of childhood characterized by nephrotic syndrome, nephroblastomas, and genital developmental abnormalities. These children present with rapidly progressive renal failure, leading to kidney transplantation at a median age of 3.6 years. In a study of the French cohort of patients with Denys-Drash syndrome, a high risk of lymphoproliferative syndrome was observed (20%). This frequency is significantly higher than in the general transplant population (4%).

The aim of the study is to evaluate the risk of post-transplant lymphoproliferative disorder following kidney transplantation in patients with Denys-Drash syndrome compared to patients with kidney transplant patients without Denys-Drash syndrome.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

Denys-Drash syndrome is a rare genetic disorder of childhood characterized by nephrotic syndrome, nephroblastomas, and genital developmental abnormalities. These children present with rapidly progressive renal failure, leading to kidney transplantation at a median age of 3.6 years. In a study of the French cohort of patients with Denys-Drash syndrome, a high risk of lymphoproliferative syndrome was observed (20%). This frequency is significantly higher than in the general transplant population (4%).

The aim of the study is to evaluate the risk of post-transplant lymphoproliferative disorder following kidney transplantation in patients with Denys-Drash syndrome compared to patients with kidney transplant patients without Denys-Drash syndrome.

The study hypothesizes that there is an increased risk of lymphoproliferative disorder in children with Denys-Drash syndrome. If this hypothesis is confirmed, it would allow for the development of active treatment methods to combat post-transplant lymphoproliferative disorder in this population.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient must be a minor at the time of kidney transplantation
  • Diagnosis of Denys-Drash syndrome (WT1 pathogenic variants in exons 8 or 9) for cases
  • Controls: minor patient, kidney transplanted at the same center as the case, immediately before and immediately after the case
  • Kidney transplant recipient on immunosuppressants
  • Hospital follow-up in a participating center in France
  • Regardless of their Epstein-Barr virus status before transplantation
  • Between 2000 and 2022
  • Holders of parental authority or adult patients informed of the study and not objecting to the processing of medical data for the study

Exclusion criteria

  • History of lymphoproliferative disorder prior to transplantation
  • Other hematopoietic cancer
  • Other genetic disease with a proven increased risk of lymphoproliferative disorder

Treatment and study plan

Collection of data from the patient's medical file

Other

Collection of data from the patient's medical file. The data will be collected until 2024.

Primary outcomes

  1. Occurrence of lymphoproliferative disorder

    Time frame: Up to 24 years

    Occurrence of lymphoproliferative disorder, confirmed by anatomopathological analyses of lymph node biopsies or of another affected site.

Secondary outcomes

  1. Description of risk factors of post-transplant lymphoproliferative disorder following kidney transplantation

    Time frame: Up to 24 years

    Investigate risk factors for post-transplant lymphoproliferative disorder following kidney transplantation in patients with Denys Drash syndrome.

    Description of the following factors: increase or secondary positivity of Epstein-Barr virus PCR, donor and recipient Epstein-Barr virus serology before transplantation, patient age at the time of transplantation.

  2. Comparison of the time to onset of post-transplant lymphoproliferative disorder following kidney transplantation

    Time frame: Up to 24 years

    Time to onset of post-transplant lymphoproliferative disorder following kidney transplantation in patients with Denys-Drash syndrome compared to patients without this syndrome.

Study contacts

Contact information is provided by the study sponsor or research team.

Hélène Morel

CONTACT

[email protected]

33171196346

Mathilde M.D. Grapin

CONTACT

[email protected]

0033142192726

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • URC-CIC Paris Descartes Necker Cochin

Registry information

Official study title

Post-transplant Lymphoproliferative Disorder Following Kidney Transplantation in Denys-Drash Syndrome: a Case-control Study

Acronym: DRASH-PTLD

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
May 26, 2026
Registry last updated
May 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.